What Causes Deep Gray Matter Atrophy in Multiple Sclerosis?

References

1. 1.↵
   2. Eshaghi A,
   3. Marinescu RV,
   4. Young AL, et al

   . Progression of regional grey matter atrophy in multiple sclerosis. Brain 2018;141:1665–77 doi:10.1093/brain/awy088 pmid:29741648

   CrossRefPubMed
2. 2.↵
   2. Eshaghi A,
   3. Prados F,
   4. Brownlee WJ, et al

   . Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 2018;83:210–22 doi:10.1002/ana.25145 pmid:29331092

   CrossRefPubMed
3. 3.↵
   2. Eijlers AJ,
   3. Van Geest Q,
   4. Dekker I, et al

   . Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain 2018;141:2605–18 doi:10.1093/brain/awy202 pmid:30169585

   CrossRefPubMed
4. 4.↵
   2. Zivadinov R,
   3. Havrdová E,
   4. Bergsland N, et al

   . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268:831–41 doi:10.1148/radiol.13122424 pmid:23613615

   CrossRefPubMed
5. 5.↵
   2. Azevedo CJ,
   3. Cen SY,
   4. Khadka S, et al

   . Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol 2018;83:223–34 doi:10.1002/ana.25150 pmid:29328531

   CrossRefPubMed
6. 6.↵
   2. Minagar A,
   3. Barnett MH,
   4. Benedict RH, et al

   . The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013;80:210–19 doi:10.1212/WNL.0b013e31827b910b pmid:23296131

   Abstract/FREE Full Text
7. 7.↵
   2. Schoonheim MM,
   3. Meijer KA,
   4. Geurts JJ

   . Network collapse and cognitive impairment in multiple sclerosis. Front Neurol 2015;6:82 doi:10.3389/fneur.2015.00082 pmid:25926813

   CrossRefPubMed
8. 8.↵
   2. Kipp M,
   3. Wagenknecht N,
   4. Beyer C, et al

   . Thalamus pathology in multiple sclerosis: from biology to clinical application. Cell Mol Life Sci 2015;72:1127–47 doi:10.1007/s00018-014-1787-9 pmid:25417212

   CrossRefPubMed
9. 9.↵
   2. Pontillo G,
   3. Cocozza S,
   4. Lanzillo R, et al

   . Determinants of deep gray matter atrophy in multiple sclerosis: a multimodal MRI study. AJNR Am J Neuroradiol 2019;40:99–106 doi:10.3174/ajnr.A5915

   Abstract/FREE Full Text
10. 10.↵
    2. Larochelle C,
    3. Uphaus T,
    4. Prat A, et al

    . Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology? Trends Neurosci 2016;39:325–39 doi:10.1016/j.tins.2016.02.001 pmid:26987259

    CrossRefPubMed
11. 11.↵
    2. Gaetano L,
    3. Häring DA,
    4. Radue EW, et al

    . Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Neurology 2018;90:e1324–32 doi:10.1212/WNL.0000000000005292 pmid:29540589

    Abstract/FREE Full Text
12. 12.↵
    2. Ziemssen T,
    3. Derfuss T,
    4. de Stefano N, et al

    . Optimizing treatment success in multiple sclerosis. J Neurol 2016;263:1053–65 doi:10.1007/s00415-015-7986-y pmid:26705122

    CrossRefPubMed
13. 13.↵
    2. Schoonheim MM,
    3. Meijer KA,
    4. Geurts JJ

    . Network collapse and cognitive impairment in multiple sclerosis. Front Neurol 2015;6:82 doi:10.3389/fneur.2015.00082 pmid:25926813

    CrossRefPubMed
14. 14.↵
    2. Wagenknecht N,
    3. Becker B,
    4. Scheld M, et al

    . Thalamus degeneration and inflammation in two distinct multiple sclerosis animal models. J Mol Neurosci 2016;60:102–14 doi:10.1007/s12031-016-0790-z pmid:27491786

    CrossRefPubMed
15. 15.↵
    2. van de Pavert SH,
    3. Muhlert N,
    4. Sethi V, et al

    . DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime? J Neurol Neurosurg Psychiatry 2016;87:461–67 doi:10.1136/jnnp-2014-310142 pmid:25926483

    Abstract/FREE Full Text
16. 16.↵
    2. Cifelli A,
    3. Arridge M,
    4. Jezzard P, et al

    . Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650–53 doi:10.1002/ana.10326 pmid:12402265

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Vercellino M,
    3. Masera S,
    4. Lorenzatti M, et al

    . Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009;68:489–502 doi:10.1097/NEN.0b013e3181a19a5a pmid:19525897

    CrossRefPubMed
18. 18.↵
    2. Rissanen E,
    3. Tuisku J,
    4. Vahlberg T, et al

    . Microglial activation, white matter tract damage, and disability in MS. Neurol Neuroimmunol Neuroinflamm 2018;5:e443 doi:10.1212/NXI.0000000000000443 pmid:29520366

    Abstract/FREE Full Text
19. 19.↵
    2. Herranz E,
    3. Gianni C,
    4. Louapre C, et al

    . Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol 2016;80:776–90 doi:10.1002/ana.24791 pmid:27686563

    CrossRefPubMed
20. 20.↵
    2. Schweser F,
    3. Raffaini Duarte Martins AL,
    4. Hagemeier J, et al

    . Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: a proposed mechanistic relationship between inflammation and oligodendrocyte vitality. Neuroimage 2018;167:438–52 doi:10.1016/j.neuroimage.2017.10.063 pmid:29097315

    CrossRefPubMed